Loading...
•
Mar 31, 2022
4DMT Q1 2022 Earnings Report
4DMT reported first quarter 2022 financial results and provided corporate updates.
Key Takeaways
4D Molecular Therapeutics reported first quarter 2022 financial results, including revenue of $1.2 million and a net loss of $26.3 million. The company highlighted progress in its clinical programs and the completion of its commercial-scale GMP manufacturing facility.
Dosed the first patient in its Phase 1/2 clinical trial of 4D-710 in patients with cystic fibrosis.
Presented updated clinical data from the ongoing Phase 1/2 clinical trial of 4D-310 in patients with Fabry disease at the 18th Annual WORLDSymposium.
Presented choroideremia natural history study data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting.
Completed the build out of a commercial-scale GMP manufacturing facility at our Emeryville headquarters which is expected to provide clinical trial material for each of our five product candidates across three therapeutic areas.
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com Forward Guidance
4D Molecular Therapeutics provided updates on expected upcoming milestones, including initial clinical data from the 4D-150 Phase 1/2 clinical trial for wet AMD in mid-2023 and a clinical data update from the 4D-310 Phase 1/2 clinical trial of 4D-310 in Fabry disease in the first half of 2023.
Positive Outlook
- Provide initial clinical data from the 4D-150 Phase 1/2 clinical trial for wet AMD in mid-2023
- Provide clinical data update from the 4D-310 Phase 1/2 clinical trial of 4D-310 in Fabry disease in the first half of 2023
- Continue enrollment and follow-up in the 4D-710 Phase 1/2 clinical trial for cystic fibrosis
- Continue enrollment and follow-up in the Phase 1/2 clinical trials for both 4D-125 for X-linked retinitis pigmentosa and 4D-110 for choroideremia and provide program updates in the first half of 2023